Drug intelligence / Profile preview

ING-008

Development stage: Unknown
Lead developer: Innospera Pharma
Modality: Small Molecules

Overview

ING-008 is a discovery-stage small molecule developed by Innospera Pharma. It is characterized as a next-generation lipid-mimetic designed to modulate an undisclosed G protein-coupled receptor (GPCR). This approach leverages Innospera's platform for creating small molecules that mimic natural lipids to target GPCRs involved in various physiological processes. The specific therapeutic indication for ING-008 has not yet been disclosed by the company, though it represents a pipeline expansion following their lead candidate, ING-006.

Beyond the preview

Go deeper on ING-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ING-008.

Explore the full profile